Epstein Secrets

r executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in

l College of Physicians of Edinburgh and a Fellow of the Faculty of Pharmaceutical Physicians. DACART CAPITAL LLC EFTA_R1_01138847 EFTA02295573 Advisory Board Pamela R. Contag, Ph.D. Dr. Contag most recently served as Founder and CEO of Cobalt Technologies, Inc. a venture- backed biofuels company, and rai

r executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in

balt Biofuels Mar-07 II ,„„-13 Series B Series E $17M $117M 4) cr 1 .UU nn 36.2% IRR 4)O& / nn .OO DiNGART C_APIIAL LL, EFTA00506151 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipien

r executive positions with Quantanova and Scotia Holdings, plc. Prior to that, Dr. Dow was head of Global Drug Development with Hoffman-La Roche in Basel, Switzerland and previously was with Syntex Corporation for over 10 years in various senior positions in drug development. Dr. Dow holds a B.Sc. in

ly • Competitive fees — 2%/20% Target >25% ROI for the portfolio. 3x return in 5 years, 5x return in 7 years DACARI CAPI I AL LL, EFTA00506197 Advisory Board Thomas Shenk, • Dr. Shenk is the Elkins Professor in the Department of Molecular Biology at Princeton University. Professor Shenk is the recipien